Bristol Myers Squibb Company $BMY Shares Acquired by Brown Lisle Cummings Inc.

Brown Lisle Cummings Inc. lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 13.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,000 shares of the biopharmaceutical company’s stock after purchasing an additional 2,262 shares during the period. Brown Lisle Cummings Inc.’s holdings in Bristol Myers Squibb were worth $880,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in BMY. Brighton Jones LLC increased its stake in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 4,935 shares during the last quarter. Park Square Financial Group LLC bought a new stake in shares of Bristol Myers Squibb in the fourth quarter worth $26,000. Centaurus Financial Inc. increased its stake in shares of Bristol Myers Squibb by 11.5% in the fourth quarter. Centaurus Financial Inc. now owns 12,175 shares of the biopharmaceutical company’s stock worth $689,000 after buying an additional 1,256 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Bristol Myers Squibb by 34.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 470,526 shares of the biopharmaceutical company’s stock worth $26,613,000 after buying an additional 120,192 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its stake in shares of Bristol Myers Squibb by 15.5% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 10,031 shares of the biopharmaceutical company’s stock worth $612,000 after buying an additional 1,344 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

BMY has been the topic of a number of research reports. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a report on Tuesday, August 5th. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Wall Street Zen cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Daiwa America cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Finally, Citigroup dropped their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $56.38.

Bristol Myers Squibb Stock Performance

BMY stock opened at $44.12 on Friday. The company has a market capitalization of $89.80 billion, a P/E ratio of 17.79, a PEG ratio of 2.22 and a beta of 0.35. The company has a 50-day simple moving average of $46.63 and a 200 day simple moving average of $49.15. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.6%. Bristol Myers Squibb’s payout ratio is currently 100.00%.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.09% of the stock is owned by corporate insiders.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.